Immune checkpoint inhibitors (ICIs) targeting PD-1 (CD279), PD-L1 (CD274), or CTLA-4 (CD152) have revolutionized cancer immunotherapy, leading to significant survival benefits in multiple cancer types (Wallis et al, 2019). This evidence concerns the gene CTLA4 and cancer.